Document is current
Any future updates will be listed below
-
Authors
Wang, Zhenyan https://orcid.org/0000-0003-1402-6570
Liu, Li
Chen, Jun
Wang, Jiangrong
Shen, Yinzhong
Qi, Tangkai
Tang, Yang
Song, Wei
Sun, Jianjun
Xu, Shuibao
Yang, Junyang
Chen, Youming
Shao, Yueming
Zhang, Renfang
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05493969 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity
https://doi.org/10.1007/s40121-026-01363-y
-
Funding
Funding for this research was provided by:
ViiV Healthcare (214248)
- License Information
-
More Information
Article History
Received: 23 February 2026
Accepted: 5 May 2026
First Online: 20 May 2026
Declarations
:
: Zhenyan Wang, Li Liu, Jun Chen, Jiangrong Wang, Yinzhong Shen, Tangkai Qi, Yang Tang, Wei Song, Jianjun Sun, Shuibao Xu, Junyang Yang, Youming Chen, Yueming Shao and Renfang Zhang declare no competing interests.
: All participants provided informed written consent before being enrolled in the study. All data were de-identified and analyzed anonymously. This study was registered on ClinicalTrials.gov (NCT05493969). This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments and received ethical approval from the Ethics Committee of SPHCC (approval number: 2021-S023-04).
